title: [A case of local recurrence of rectal cancer in long-term responding to combined therapy of low-dose CPT-11 and 5'-DFUR].
abstract: A 68-year-old man underwent Miles'operation for advanced rectal cancer. Local recurrence occurred 9 months following the operation. We started the combined therapy of low-dose CPT-11 and doxifluridine (5'-DFUR). CPT-11 was administered at 80 mg/body biweekly and 5'-DFUR was orally administered at 800 mg/day/body on day 3-7. We then reduced the CPT-11 dose to 60 mg/body because of neutropenia. Four months later,we obtained a decrease in the tumor marker (carcinoembryonic antigen: CEA) to the normal serum level, and stopped the medication. However, 3 months later the serum CEA level was increased, and we restarted the same therapy. Six months after restarting this therapy, the serum CEA level decreased to the normal level,and the local recurrence was decreased in size. We finished this combined therapy and changed to 5'-DFUR only. No tumor progression or recurrences in this patient are seen 2 years after completing this combined therapy.
authors.affiliation: Dept. of Surgery, Asahikawa Kosei Hospital.
authors.forename: Junichi
authors.initials: J
authors.lastname: Gotoh
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Akabane
authors.forename: Kengo
authors.initials: K
authors.lastname: Kita
authors.forename: Masato
authors.initials: M
authors.lastname: Fujiyoshi
authors.forename: Gentaro
authors.initials: G
authors.lastname: Hirokata
authors.forename: Koji
authors.initials: K
authors.lastname: Imai
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Kawai
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Yanagida
authors.forename: Shiro
authors.initials: S
authors.lastname: Nakano
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002272:Carcinoembryonic Antigen / Q000097:blood; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D012074:Remission Induction
chemical_list: D002272:Carcinoembryonic Antigen; D005467:Floxuridine; D000077146:Irinotecan; C025034:doxifluridine; D002166:Camptothecin